Greenleaf Peter 4/A

What Happened

• Peter Greenleaf, a director of Pelthos Therapeutics, was granted 25,478 restricted stock units (RSUs) on July 2, 2025. The Form 4 (amended) reports the award at $0 per share (total $0) — this is an equity award, not a purchase or sale. The amendment was filed Apr 1, 2026 to report the grant in Table I (it was originally reported in Table II).

Key Details

• Transaction date: July 2, 2025; Form 4 amendment filed: April 1, 2026.
• Transaction type/code: A — Grant/Award of RSUs; reported grant price $0.00.
• Shares granted: 25,478 RSUs (each RSU represents the right to one share of common stock upon settlement).
• Shares owned after transaction: Not specified in the provided amendment.
• Vesting / restrictions (footnotes): initial one‑third vested on July 2, 2025; remaining two‑thirds vest in equal quarterly installments over the next two years, subject to continued service. RSUs may be settled only in shares of common stock.
• Filing note: This is an amended Form 4 (Exhibit 24 — Power of Attorney). The amendment was filed many months after the grant date, so the public disclosure was delayed.

Context

• RSUs are a compensation award that convert to shares upon vesting/settlement; they are not an open‑market purchase or sale. The initial one‑third vesting means some portion became vested on July 2, 2025, but settlement timing (when vested RSUs are converted to shares) is not detailed here. Because this is an award rather than a purchase, it should be viewed as compensation, not a direct market buy or sell.